Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part …


Novartis takes license on Celyad's allogeneic CAR T cells

Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s …

POPULAR TAGS

Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Written by LVS on in the category news with the tags , .


Bone Therapeutics today announced it has been granted EUR 2.3 million in non-dilutive funding to support its research programs. This funding has been granted by the Walloon Region by decision of the Minister for Economy, Industry, Innovation and New Technologies, Mr Jean-Claude Marcourt.

You can find an overview of all Bone Therapeutics news here.

Thomas Lienard, CEO of Bone Therapeutics commented: "We are grateful to the Walloon Region, and in particular to the Minister for Economy Mr Jean-Claude Marcourt, for its continued support of the company. This support allows the company to leverage its available equity funding in order to support ongoing research initiatives designed to maximize the potential of its product candidates and further improve the quality of our cell therapy products."

The funding will cover up to 52% of expenses related to three new research projects. The first two projects have been designed to further investigate the application of the allogeneic product ALLOB® for potential additional indications and patient populations. A third project aims to further optimize the production and logistics of our cellular products. The funding covers a two-year research period.

Read more about: , .

RELATED ARTICLES
IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million e…


Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part …


Novartis takes license on Celyad's allogeneic CAR T cells

Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s …

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio Itera Life Science Turnstone XpandInnovation Janssen GSK V-Bio Ventures KU Leuven UGent Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.